Could or Should We Use MCDA in the French HTA Process?

Pharmacoeconomics. 2019 Dec;37(12):1417-1419. doi: 10.1007/s40273-019-00846-w.

Authors

Salah Ghabri¹, Jean-Michel Josselin², Benoît Le Maux²

Affiliations

¹ Department of Economic and Public Health Evaluation, French National Authority for Health (Haute Autorité de Santé, HAS), 5 Avenue du Stade de France, 93218, Saint-Denis La Plaine Cedex, France. [email protected].
² Faculty of Economics, University of Rennes 1, CREM-CNRS, Place Hoche 7, 35065, Rennes cedex, France.

PMID: 31565761
DOI: 10.1007/s40273-019-00846-w

No abstract available

Publication types

Editorial

MeSH terms

Cost-Benefit Analysis
Decision Making
Decision Support Techniques*
Delivery of Health Care / economics*
Delivery of Health Care / standards
Drug Costs
Equipment and Supplies / economics
France
Humans
Quality-Adjusted Life Years
Technology Assessment, Biomedical / economics*